244 related articles for article (PubMed ID: 19195054)
1. Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis.
Brunetto MR; Colombatto P; Bonino F
World J Gastroenterol; 2009 Feb; 15(5):531-7. PubMed ID: 19195054
[TBL] [Abstract][Full Text] [Related]
2. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
Fontaine H; Alric L; Labreuche J; Legendre B; Louvet A; Antoine C; Legendre CM; Hazzan M; Kamar N; Dharancy S; Pol S; Duhamel A; Mathurin P
J Hepatol; 2019 May; 70(5):831-838. PubMed ID: 30879789
[TBL] [Abstract][Full Text] [Related]
3. Modelling of viral dynamics in hepatitis B and hepatitis C clinical trials.
Sypsa V; Hatzakis A
Stat Med; 2008 Dec; 27(30):6505-21. PubMed ID: 18951370
[TBL] [Abstract][Full Text] [Related]
4. Expressions of inhibitory checkpoint molecules in acute and chronic HBV and HCV infections: Implications for therapeutic monitoring and personalized therapy.
Hakim MS; Rahmadika N; Jariah ROA
Rev Med Virol; 2020 Mar; 30(2):e2094. PubMed ID: 31825155
[TBL] [Abstract][Full Text] [Related]
5. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
6. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
7. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
[TBL] [Abstract][Full Text] [Related]
8. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
9. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
Chehadeh W; Al-Nakib W
J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
[TBL] [Abstract][Full Text] [Related]
10. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
[TBL] [Abstract][Full Text] [Related]
11. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients.
Yeh ML; Huang CI; Huang CF; Hsieh MH; Liu TW; Lin YH; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Kuo PL; Dai CY; Yu ML; Chuang WL
J Infect Dis; 2019 Apr; 219(8):1224-1233. PubMed ID: 30452671
[TBL] [Abstract][Full Text] [Related]
13. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
[TBL] [Abstract][Full Text] [Related]
14. Viral dynamics in hepatitis B virus infection.
Nowak MA; Bonhoeffer S; Hill AM; Boehme R; Thomas HC; McDade H
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4398-402. PubMed ID: 8633078
[TBL] [Abstract][Full Text] [Related]
15. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.
Tsiang M; Rooney JF; Toole JJ; Gibbs CS
Hepatology; 1999 Jun; 29(6):1863-9. PubMed ID: 10347131
[TBL] [Abstract][Full Text] [Related]
16. Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection.
Cheruvu S; Marks K; Talal AH
Clin Liver Dis; 2007 Nov; 11(4):917-43, ix-x. PubMed ID: 17981235
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):26-30. PubMed ID: 24199625
[TBL] [Abstract][Full Text] [Related]
18. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.
Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR;
Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of chronic hepatitis B and C virus infections in the clinical practice].
Panther E; Thimme R
Praxis (Bern 1994); 2012 Jan; 101(1):37-42. PubMed ID: 22219073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
